ICON Public Limited Company provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company was founded in 1990 and is based in Dublin, Ireland.
ICLR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for ICLR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Icon Plc ranked in the 40th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Icon Plc, consider:
Interest coverage, a measure of earnings relative to interest payments, is 33.02; that's higher than 88.53% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 13.59% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
ICLR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.37% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ICLR, try STE, REGN, GILD, MEDP, and CRL.
Global Healthcare Cro Market Size Study, By Type (Drug Discovery, Pre-Clinical, Clinical), By Service (Project Management, Data Management, Medical Writing, Technology) And By Regional Forecasts 2025, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been recognised in the 2020 Forbes List of America’s Best Employers for Women for the second consecutive year. Forbes collaborated with market research firm Statista, surveying 75,000 Americans, including 45,000 women, working for businesses that employ more than 1,000 workers
Moody's Investors Service, ("Moody's") has today affirmed the Baa3 long term issuer rating of ICON Plc ("ICON" or "the company"). ICON is strongly positioned in the Baa3 rating. Additionally, Moody's expects that ICON will continue to have strong Moody's-adjusted EBITDA margins of around 18% to 19%.
Investment Thesis Icon PLC 5-year share price performance. Source: TradingView. Icon (ICLR) looks like a solid investment opportunity in the contract research organization ("CRO") space, offering strong growth potential whilst being a little undervalued by the market, based on my analysis. Since 2010 Icon has grown its revenues from $0.9bn,...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]